A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching From BRACET/Gilenya® to Natalizumab in Subjects With Relapsing Forms of Multiple Sclerosis (MS)

Trial Profile

A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching From BRACET/Gilenya® to Natalizumab in Subjects With Relapsing Forms of Multiple Sclerosis (MS)

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms ESCALATE
  • Sponsors Biogen
  • Most Recent Events

    • 08 Jan 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 18 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 22 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top